This is a real promise of hope for 2000 French patients suffering from esophageal cancer with metastases.
Keytruda, the immunotherapy treatment of the American laboratory MSD (Merck in the United States), has just been authorized in France by the High Authority for Health (HAS).
Clinical trials have demonstrated its superiority over existing treatment, based on chemotherapy.
This is the tenth indication for Keytruda approved in France (colorectal, endometrium, breast, etc.).
"
It's a drug that is revolutionizing the treatment of this disease,
" rejoices Clarisse Lhoste, head of MSD France.
It has become the reference treatment in many cancers
.
To discover
Taxes 2022: all about your tax return
Presidential 2022: find here the result of the first round of the election
Read also
Immunotherapy: the revolution is underway against cancer
The HAS has given the green light to the availability of Keytruda in metastatic esophageal cancer even though it is still under review by the European Medicines Agency.
This is made possible by the reform of early access, promised by the public authorities last summer during…
This article is for subscribers only.
You have 75% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for 1€ the first month
I ENJOY IT
Already subscribed?
Login